KEY INDUSTRY DEALS
Companies Agree to Jointly Commercialize SER-109 Investigational Microbiome Therapeutic to Treat Recurrent C. difficile Infection, Leading the Way for Entirely New Treatment Modality Deal calls for more than $500 million in upfront and contingent milestone payments Seres Therapeutics to conduct a conference call at 8:30 a.m. ET CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Seres Therapeutics, Inc.
Continue ReadingSEATTLE – (BUSINESS WIRE) – Accelerator Life Science Partners (“ALSP”), a leading early-stage life science accelerator and investment firm, today announced that its portfolio company, Lodo Therapeutics Corporation (“Lodo” or the “Company”), has been acquired by Zymergen Inc. (NASDAQ: ZY) for an undisclosed amount. The transaction is the third exit from ALSP’s investment fund, Accelerator
Continue ReadingGenetic Engineering & Biotechnology News (May 11, 2021) Synthetic biology powerhouse Ginkgo Bioworks said today it will become a public company through a $17.5 billion merger with a special purpose acquisition company (SPAC) that is expected to provide up to $2.5 billion of gross cash proceeds. The SPAC business combination with Soaring Eagle Acquisition Corp.
Continue ReadingMichael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer, to join Vedanta’s Scientific Advisory Board CAMBRIDGE, January 12, 2021 – Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced that Pfizer Inc. (NYSE: PFE)
Continue ReadingImmediately Positions Gilead as a Leader in Cell Therapy Kite’s Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation Leverages Gilead’s Expertise in Rapidly Advancing Therapies to Address Unmet Patient
Continue Reading